BioPharma Dive January 22, 2026
The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be as effective in spurring weight loss as injectable therapies.
Dive Brief:
- Corxel Pharmaceuticals, a New Jersey-based biotechnology company, announced Thursday it raised $287 million in a Series D1 funding round meant to push an obesity drug into further testing.
- Corxel gained development rights to its lead program, an oral GLP-1 medicine called CX11, from the Chinese drugmaker Vincentage in 2024. CX11 is in mid-stage testing in the U.S. in obese and overweight patients. Vincentage is running a Phase 3 study in China.
- The biotech will launch a global Phase 2 study in type 2 diabetes this year...
Today's Sponsors
Today's Sponsor